Journal of Antibiotics 1983-12-01

Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I. Taxonomy, fermentation and biological properties.

J B Tunac, B D Graham, W E Dobson

Index: J. Antibiot. 36 , 1595-1600, (1983)

Full Text: HTML

Abstract

CI-920 (PD 110,161) and two analogues (PD 113,270 and PD 113,271) are novel antitumor compounds produced by a new actinomycete characterized as Streptomyces pulveraceus subsp. fostreus ATCC 31906. The antitumor compounds are predominantly produced during the stationary (idiophase) growth phase of the organism. CI-920 is active versus the murine P388 lymphocytic and L1210 lymphoid leukemia with T/C values of 246 and 207, respectively. This compound has no significant antimicrobial activity.

Related Compounds

  • Fostriecin

Related Articles:

Dopamine D2 receptor activity modulates Akt signaling and alters GABAergic neuron development and motor behavior in zebrafish larvae.

2011-04-06

[J. Neurosci. 31 , 5512-25, (2011)]

Fostriecin-mediated G2-M-phase growth arrest correlates with abnormal centrosome replication, the formation of aberrant mitotic spindles, and the inhibition of serine/threonine protein phosphatase activity.

1998-08-15

[Cancer Res. 58 , 3611-3619, (1998)]

Fostriecin, an antitumor antibiotic with inhibitory activity against serine/threonine protein phosphatases types 1 (PP1) and 2A (PP2A), is highly selective for PP2A.

1997-10-27

[FEBS Lett. 416 , 230, (1997)]

Purification of protein phosphatase 4 catalytic subunit: inhibition by the antitumour drug fostriecin and other tumour suppressors and promoters.

1998-07-24

[FEBS Lett. 431 , 357-361, (1998)]

Novel antitumor agents CI-920, PD 113,270 and PD 113,271. II. Isolation and characterization.

1983-12-01

[J. Antibiot. 36 , 160-1605, (1983)]

More Articles...